TAF6

Across TCGA pan-cancer cohorts, TAF6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TAF6 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TAF6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TAF6 expression acts as an unfavorable survival marker, although some lineages such as OV and PDAC show a favorable association.

OV, PDAC, and LUAD are the cancer types where TAF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	1.000	0.677	.019	8	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	7	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.728	.018	7	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.492	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TAF6–OV (DFS)

Open the OV breakdown →